As Congress debates the latest patent reform legislation, some are proposing changes to Patent Trial and Appeal Board (PTAB) practice that may undermine one of the success stories from the 2011 patent reform law. The changes seem motivated by the perception that the PTAB’s cancellation rate is either too high or that the Board has been hijacked by hedge funds for personal gain. But the forces behind this latest push for “reform” (many of whom have financial interests in the outcome) may just want a poison pill aimed at preventing passage of the legislation. I believe amending or changing these new proceedings should be based on accurate data, rather than fear and anecdote.
top of page
Recent Posts
See AllIn a joint coalition letter, UFPR urged the Senate Judiciary Committee to not move forward with the PREVAIL Act, pointing to the many ways the proposed legislation would unreasonably impede businesses
UFPR Co-Chairs Stephanie Martz and Chris Mohr authored an op-ed in Real Clear Markets about newly proposed rules from the USPTO. Efforts that undermine our robust IPR system will make American busines
United for Patent Reform (UFPR) today issued the following statement in opposition of the recently introduced PREVAIL Act, a bill that would essentially repeal a fundamental pillar of the America Inve
bottom of page